Chief Executive Officer
Emma joined Isogenica as Chief Executive Officer in September 2018. She is passionate about technologies that can accelerate drug discovery and development, and experienced in leading highly innovative, scientific companies from start-up through multiple product launches, to rapidly growing sustainable businesses. Before joining Isogenica, Dr Sceats, was CEO of CN Bio Innovations, which she grew from a Oxford University spin-out to a recognised leader in human Organ-on-Chip technologies.
Dr Sceats was instrumental in the development and execution of CN Bio’s vision, resulting in strong revenue growth, rapid development of two innovative new products, and a pioneering partnership with the Food and Drug Administration to characterise the use of Organs-on-Chips in drug development and regulatory evaluation. Earlier in her career Emma was a technology manager at Oxford University Innovation, responsible for patenting, marketing and licensing technologies developed at the university and building spin-out companies to exploit IP.
Emma was a Presidential scholar in chemistry at the Massachusetts Institute of Technology and a graduate scholar at the University of Oxford (DPhil, Chemistry).